Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems.
Abstract
BACKGROUND: Stage at diagnosis plays a significant role in colorectal cancer (CRC)
survival. Understanding which factors contribute to a more advanced stage at diagnosis
is vital to improving overall survival. Comorbidity, race, and age are known to impact
receipt of cancer therapy and survival, but the relationship of these factors to stage
at diagnosis of CRC is less clear. The objective of this study is to investigate how
comorbidity, race and age influence stage of CRC diagnosis. METHODS: Two distinct
healthcare populations in the United States (US) were retrospectively studied. Using
the Cancer Care Outcomes Research and Surveillance Consortium database, we identified
CRC patients treated at 15 Veterans Administration (VA) hospitals from 2003-2007.
We assessed metastatic CRC patients treated from 2003-2006 at 10 non-VA, fee-for-service
(FFS) practices. Stage at diagnosis was dichotomized (non-metastatic, metastatic).
Race was dichotomized (white, non-white). Charlson comorbidity index and age at diagnosis
were calculated. Associations between stage, comorbidity, race, and age were determined
by logistic regression. RESULTS: 342 VA and 340 FFS patients were included. Populations
differed by the proportion of patients with metastatic CRC at diagnosis (VA 27% and
FFS 77%) reflecting differences in eligibility criteria for inclusion. VA patients
were mean (standard deviation; SD) age 67 (11), Charlson index 2.0 (1.0), and were
63% white. FFS patients were mean age 61 (13), Charlson index 1.6 (1.0), and were
73% white. In the VA cohort, higher comorbidity was associated with earlier stage
at diagnosis after adjusting for age and race (odds ratio (OR) 0.76, 95% confidence
interval (CI) 0.58-1.00; p = 0.045); no such significant relationship was identified
in the FFS cohort (OR 1.09, 95% CI 0.82-1.44; p = 0.57). In both cohorts, no association
was found between stage at diagnosis and either age or race. CONCLUSION: Higher comorbidity
may lead to earlier stage of CRC diagnosis. Multiple factors, perhaps including increased
interactions with the healthcare system due to comorbidity, might contribute to this
finding. Such increased interactions are seen among patients within a healthcare system
like the VA system in the US versus sporadic interactions which may be seen with FFS
healthcare.
Type
Journal articleSubject
Age FactorsAged
Colorectal Neoplasms
Comorbidity
Continental Population Groups
Delivery of Health Care
Early Detection of Cancer
Fee-for-Service Plans
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Retrospective Studies
United States
United States Department of Veterans Affairs
Permalink
https://hdl.handle.net/10161/16116Published Version (Please cite this version)
10.1186/1471-2407-8-345Publication Info
Zafar, S Yousuf; Abernethy, Amy P; Abbott, David H; Grambow, Steven C; Marcello, Jennifer
E; Herndon, James E; ... Provenzale, Dawn T (2008). Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective,
parallel analysis of two health systems. BMC Cancer, 8. pp. 345. 10.1186/1471-2407-8-345. Retrieved from https://hdl.handle.net/10161/16116.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Amy Pickar Abernethy
Adjunct Professor in the Department of Medicine
Amy P. Abernethy, MD PhDDirector, Center for Learning Health Care Director, Duke Cancer
Care Research Program Professor of Medicine, Department of Medicine, Division of Medical
Oncology, Duke University School of Medicine Associate Professor of Nursing, Duke
University School of NursingDr. Abernethy, a hematologist/oncologist and palliative
care physician, is Professor of Medicine in the Duke University School of Medicine,
Director of the Duke Center for Learn
This author no longer has a Scholars@Duke profile, so the information shown here reflects
their Duke status at the time this item was deposited.
Steven C. Grambow
Associate Professor of Biostatistics & Bioinformatics
I am an academic statistician with a focus on educational leadership and administration,
teaching, mentoring, and collaborative clinical research. I serve as the director
of multiple education programs, both formal degree programs and certificate-based
training programs. I also provide administrative oversight of multiple graduate degree
programs and educational initiatives focusing on clinical and translational science
workforce development at the student, staff, and faculty levels.
James Emmett Herndon II
Professor of Biostatistics & Bioinformatics
Current research interests have application to the design and analysis of cancer clinical
trials. Specifically, interests include the use of time-dependent covariables within
survival models, the design of phase II cancer clinical trials which minimize some
of the logistical problems associated with their conduct, and the analysis of longitudinal
studies with informative censoring (in particular, quality of life studies of patients
with advanced cancer).
Dawn Tranchino Provenzale
Professor of Medicine
Dr. Provenzale is Director of GI Outcomes Research at Duke University and the Director
of the Durham Epidemiologic Research and Information Center (ERIC). She directs a
research program that integrates observational research, measurement of patient-centered
outcomes and decision making to investigate patient-oriented research questions in
gastrointestinal cancer screening, surveillance and quality of care. Dr. Provenzale
also directs the training program for GI fellows committed to careers
This author no longer has a Scholars@Duke profile, so the information shown here reflects
their Duke status at the time this item was deposited.
Syed Yousuf Zafar
Adjunct Professor in the Department of Medicine
Dr. Zafar is a gastrointestinal medical oncologist and Associate Professor of Medicine,
Public Policy, and Population Health Science at the Duke Cancer Institute and Duke-Margolis
Center for Health Policy. He serves as Director of Healthcare Innovation at the Duke
Cancer Institute. Dr. Zafar also serves as Clinical Associate Director of Duke Forge
(Health Data Science Center). Dr. Zafar is considered an international expert in identifying
and intervening upon the financial burden of cancer ca
Leah L Zullig
Professor in Population Health Sciences
Leah L. Zullig, PhD, MPH is a health services researcher and an implementation scientist.
She is a Professor in the Duke Department of Population Health Sciences and an investigator
with the Center of Innovation to Accelerate Discovery and Practice Transformation
(ADAPT) at the Durham Veterans Affairs Health Care System. Dr. Zullig’s overarching
research interests address three domains: improving cancer care delivery and quality;
promoting cancer survivorship and chr
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info